Evaluating MERS-CoV Entry Pathways
- PMID: 31883084
- PMCID: PMC7121971
- DOI: 10.1007/978-1-0716-0211-9_2
Evaluating MERS-CoV Entry Pathways
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic pathogen with a broad host range. The extent of MERS-CoV in nature can be traced to its adaptable cell entry steps. The virus can bind host-cell carbohydrates as well as proteinaceous receptors. Following receptor interaction, the virus can utilize diverse host proteases for cleavage activation of virus-host cell membrane fusion and subsequent genome delivery. The fusion and genome delivery steps can be completed at variable times and places, either at or near cell surfaces or deep within endosomes. Investigators focusing on the CoVs have developed several methodologies that effectively distinguish these different cell entry pathways. Here we describe these methods, highlighting virus-cell entry factors, entry inhibitors, and viral determinants that specify the cell entry routes. While the specific methods described herein were utilized to reveal MERS-CoV entry pathways, they are equally suited for other CoVs, as well as other protease-dependent viral species.
Keywords: Coronavirus (CoV); Endosome; HR2 peptide; IFITM3; Middle East respiratory syndrome (MERS); Protease; Protease inhibitor; Pseudovirus; Spike (S); TMPRSS2; Transfection; Viral entry; Virus concentration; Virus purification.
Figures
Similar articles
-
The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases.PLoS Pathog. 2017 Jul 31;13(7):e1006546. doi: 10.1371/journal.ppat.1006546. eCollection 2017 Jul. PLoS Pathog. 2017. PMID: 28759649 Free PMC article.
-
Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin during Viral Entry into Target Cells.J Virol. 2018 Sep 12;92(19):e00683-18. doi: 10.1128/JVI.00683-18. Print 2018 Oct 1. J Virol. 2018. PMID: 30021905 Free PMC article.
-
Ca2+ Ions Promote Fusion of Middle East Respiratory Syndrome Coronavirus with Host Cells and Increase Infectivity.J Virol. 2020 Jun 16;94(13):e00426-20. doi: 10.1128/JVI.00426-20. Print 2020 Jun 16. J Virol. 2020. PMID: 32295925 Free PMC article.
-
MERS-CoV spike protein: Targets for vaccines and therapeutics.Antiviral Res. 2016 Sep;133:165-77. doi: 10.1016/j.antiviral.2016.07.015. Epub 2016 Jul 26. Antiviral Res. 2016. PMID: 27468951 Free PMC article. Review.
-
[Development of peptidic MERS-CoV entry inhibitors].Yao Xue Xue Bao. 2015 Dec;50(12):1513-9. Yao Xue Xue Bao. 2015. PMID: 27169270 Review. Chinese.
Cited by
-
Systematic Tracing of Susceptible Animals to SARS-CoV-2 by a Bioinformatics Framework.Front Microbiol. 2022 Mar 4;13:781770. doi: 10.3389/fmicb.2022.781770. eCollection 2022. Front Microbiol. 2022. PMID: 35308363 Free PMC article.
-
Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2.bioRxiv [Preprint]. 2021 Apr 10:2021.04.08.438911. doi: 10.1101/2021.04.08.438911. bioRxiv. 2021. Update in: Elife. 2021 Dec 07;10:e73027. doi: 10.7554/eLife.73027 PMID: 33851164 Free PMC article. Updated. Preprint.
-
Adaptive variations in SARS-CoV-2 spike proteins: effects on distinct virus-cell entry stages.mBio. 2023 Aug 31;14(4):e0017123. doi: 10.1128/mbio.00171-23. Epub 2023 Jun 29. mBio. 2023. PMID: 37382441 Free PMC article.
-
MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges.Ann Clin Microbiol Antimicrob. 2021 Jan 18;20(1):8. doi: 10.1186/s12941-020-00414-7. Ann Clin Microbiol Antimicrob. 2021. PMID: 33461573 Free PMC article. Review.
-
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.Elife. 2021 Dec 7;10:e73027. doi: 10.7554/eLife.73027. Elife. 2021. PMID: 34874007 Free PMC article.
References
-
- Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/en/news-room/fact-sheets/detail/middle-east-respirat...). Accessed 4 Mar 2019
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
